|
Press Contacts
John Lacey
Associate Director, Corporate Communications
Phone: 617-768-6690
Corporate/executive issues; Massachusetts issues; Public policy; Oncology (Campath, Clolar, Fludara, Leukine); Transplant (Thymoglobulin, Mozobil); Alemtuzumab for MS and Gene therapy.
|
Lori Gorski
Associate Director, Corporate Communications
Phone: 617-768-9344
Genetic diseases (Cerezyme, Fabrazyme, Aldurazyme, Myozyme); Biosurgery (Synvisc) and Corporate Social Responsibility.
|
Erin Emlock
Associate Manager, Corporate Communications
Phone: 617-768-6923
Financial results; Renal disease (Renagel, Renvela, Hectorol); Endocrinology (Thyrogen); Cardiovascular disease (mipomersen); Diagnostics (point-of-care testing); HR topics; Facilities and Environmental initiatives.
|
Sarah Connors
Senior Corporate Communications Specialist
Phone: 617-768-6438
Genetics (reproductive and cancer testing); Cell therapies (Carticel and Epicel); Biosurgery (Seprafilm); and Community Relations.
|
Heidi De Wit
Director, Corporate Communications
International Issues
Phone: 617-768-6699
|
Caroline De Bie
Associate Director, Corporate Communications Europe
European Issues
Phone: +32 2 714 17 45
|
If you are a journalist and would prefer to send an email please contact Media Relations. For urgent inquiries, please call the appropriate press contact above.
If you are not a journalist and have a general question about Genzyme, please call our main phone number: 617-252-7500 or email our Corporate Offices.
|
Home
